Article Details
Retrieved on: 2024-01-23 12:27:40
Tags for this article:
Click the tags to see associated articles and topics
Summary
BioNTech and DualityBio have initiated a Phase III trial of BNT323/DB-1303, an antibody-drug conjugate targeting HER2-low metastatic breast cancer, leveraging biotechnology and immunology insights to improve patient outcomes.
Article found on: www.clinicaltrialsarena.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here